Global AmitriptylineMarket, By Strength (10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mgtablets, 100 mg tablets, and 150 mg tablets), By Indication (Depression,Nocturnal Enuresis, Migraine, Chronic Neuropathic Pain, and Others), by DistributionChannel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and byRegion (North America, Latin America, Europe, Asia Pacific, Middle East, andAfrica), is estimated to be valued at US$ 527.4 million in 2020 and is expectedto exhibit a CAGR of 5.3% during the forecast period (2020-2027), ashighlighted in a new report published by Coherent Market Insights.
The increasing R&D activitiesfocused on evaluating the efficiency of amitriptyline in various therapeuticareas, is expected to drive the growth of the global amitriptyline market. Forinstance, in April 2016, Boston Medical Center initiated phase 2 clinical studyto compare the effectiveness of amitriptyline versus placebo (inactivemedication) in treating chronic laryngitis. The study is expected to completein October 2022.
Global Amitriptyline Market –Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreakin December 2019, the disease has spread to over 100 countries across the globewith the World Health Organization declaring it a public health emergency.According to the World Health Organization’s report, manifestation of thecoronavirus disease (COVID-19) has resulted in more than 36.1 million infectedindividuals worldwide as of October 7, 2020.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/4226
COVID-19 has affected the economyin three main ways; by directly affecting production and demand, by creatingdisruptions in distribution channel, and by its financial impact on firms andfinancial markets. Due to nationwide lockdowns, several countries such asIndia, China, UAE, Saudi Arabia, and others are facing problems with regards totransportation of drugs from one place to another.
The coronavirus (COVID-19)pandemic and resulting lockdowns in various countries across the globe haveimpacted the financial status of businesses in all sectors. The privatehealthcare sector has been impacted significantly by the pandemic. Thelockdowns have placed an economic burden on the private as well as publichealthcare sector.
Healthcare providers were facingproblems in investing additional manpower, equipment, consumables, and otherresources to ensure safety in hospitals, provide treatment to patients withother diseases, and declining outpatient visits, etc.
Furthermore, pharmaceuticalcompanies are facing major challenges on various fronts due to the pandemic.The major challenges include disruption in supply of raw materials required formanufacturing drug formulations due to irregularities in transportation.Moreover, distributors of drug products are experiencing irregular demand fromretailers.
Browse 36 Market Data Tables and37 Figures spread through 178 Pages and in-depth TOC on “Global AmitriptylineMarket, By Strength (10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mgtablets, 100 mg tablets, and 150 mg tablets), By Indication (Depression,Nocturnal Enuresis, Migraine, Chronic Neuropathic Pain, and Others), byDistribution Channel (Hospital Pharmacies, Retail Pharmacies, and OnlinePharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,Middle East, and Africa).
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/amitriptyline-market-4226
The global amitriptyline marketgrowth is expected to be driven by high prevalence of depression andprescriptions of antidepressants. For instance, according to data published bythe American Psychological Association in 2017, there was a 64% increase in thepercentage of people using antidepressants between 1999 and 2014 in the U.S.
Key Takeaways of the GlobalAmitriptyline Market:
The global amitriptyline marketis expected to exhibit a CAGR of 5.3% during the forecast period owing to theincreasing prevalence of depression among the population, which may facilitatedemand for amitriptyline.
Moreover, research institutes arealso engaged in conducting clinical trials which is contributing to growth ofthe market. For instance, in September 2020, the University of California,Davis commenced a clinical trial to assess the physiological and behavioralmechanisms associated with amitriptyline in adult patients with functionalGERD-related symptoms. The study estimated to complete in December 2021.
Key players operating in theglobal amitriptyline market are Accord Healthcare Inc., Mylan PharmaceuticalsInc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Vintage PharmaceuticalsInc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., and TorrentPharmaceuticals Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/4226
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
